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Wiskott-Aldrich syndrome (WAS) is an X-linked 
immunodeficiency characterized by thrombo-
cytopenia, eczema, recurrent infections, and auto-
immune phenomena. The disease is caused by 
mutations of the WAS gene that encodes the 
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Mutations in Wiskott-Aldrich syndrome (WAS) protein (WASp), a regulator of actin dynamics 
in hematopoietic cells, cause WAS, an X-linked primary immunodeficiency characterized by 
recurrent infections and a marked predisposition to develop autoimmune disorders. The mech-
anisms that link actin alterations to the autoimmune phenotype are still poorly understood. 
We show that chronic activation of plasmacytoid dendritic cells (pDCs) and elevated type-I 
interferon (IFN) levels play a role in WAS autoimmunity. WAS patients display increased 
expression of type-I IFN genes and their inducible targets, alteration in pDCs numbers, and 
hyperresponsiveness to TLR9. Importantly, ablating IFN-I signaling in WASp null mice rescued 
chronic activation of conventional DCs, splenomegaly, and colitis. Using WASp-deficient mice, 
we demonstrated that WASp null pDCs are intrinsically more responsive to multimeric agonist 
of TLR9 and constitutively secrete type-I IFN but become progressively tolerant to further 
stimulation. By acute silencing of WASp and actin inhibitors, we show that WASp-mediated 
actin polymerization controls intracellular trafficking and compartmentalization of TLR9 
ligands in pDCs restraining exaggerated activation of the TLR9–IFN- pathway. Together, 
these data highlight the role of actin dynamics in pDC innate functions and imply the pDC–
IFN- axis as a player in the onset of autoimmune phenomena in WAS disease.
© 2013 Prete et al. This article is distributed under the terms of an Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months after 
the publication date (see http://www.rupress.org/terms). After six months it is 
available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
by-nc-sa/3.0/).
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and it is involved in polarization and secretion of cytokine/
cytotoxic granules in T cells/NK cells (Orange et al., 2002; 
Gismondi et al., 2004; Morales-Tirado et al., 2004; Trifari et al., 
2006). Together, the cellular defects identified in WASp-
deficient immune cells provide clues to understand the im-
munodeficiency of WAS patients. However, the mechanisms 
by which perturbation of actin dynamics promote autoim-
mune phenomena are less clear. Impairment of T and B cell 
tolerance have been reported in WAS patients and in Was-
deficient mice, but the exact cellular mechanisms that link loss 
of WASp function to autoimmunity have not been fully elu-
cidated yet (Humblet-Baron et al., 2007; Maillard et al., 2007; 
Marangoni et al., 2007; Becker-Herman et al., 2011; Recher 
et al., 2012).
Plasmacytoid DCs (pDCs) are the major class of type-I 
IFN–producing cells that react rapidly upon pathogen en-
counter to secrete large amount of this cytokine. Recognition 
of foreign nucleic acid by TLR7 and TLR9 occurs in endo-
somes and leads to production of type-I IFN and proinflam-
matory cytokines. Several studies have unveiled that activation 
of IFN regulatory factor 7 (IRF-7) and IFN- production in 
pDCs relies upon strict spatiotemporal compartmentalization 
of TLR9 and its ligands within the endocytic pathway (Honda 
et al., 2005; Guiducci et al., 2006; Sasai et al., 2010).
Besides their beneficial antiviral properties, type-I IFNs pro-
duced by pDCs contribute to breakage of tolerance in several 
WAS protein (WASp) involved in controlling actin dynamics. 
Members of the WASp family regulate a variety of actin-
dependent processes that range from cell migration to phago-
cytosis, endocytosis, and membrane trafficking (Thrasher and 
Burns, 2010). Efforts to understand the cellular basis of the 
disease have identified diverse and cell-specific actin-related 
defects in cells of the adaptive and innate immune system. In 
T cells, TCR engagement induces cytoskeletal rearrange-
ment, driving assembly of signaling platforms at the synaptic 
region. WASp plays a crucial role in this process by control-
ling ex novo actin polymerization required to stabilize synapse 
formation and signaling (Dupré et al., 2002; Sasahara et al., 
2002; Badour et al., 2003; Snapper et al., 2005; Sims et al., 
2007). WASp is also required on the APC side of the immune 
synapse for proper transmission of activating signals (Pulecio 
et al., 2008; Bouma et al., 2011). Defective signaling through 
antigen receptors affects the function of invariant natural killer 
T cells (Astrakhan et al., 2009; Locci et al., 2009) and B cells 
(Meyer-Bahlburg et al., 2008; Westerberg et al., 2008; Becker-
Herman et al., 2011). Furthermore, altered actin polymeriza-
tion and integrin signaling in WASp-deficient immune cells 
cause defective homing and directional migration of T, B, 
and DCs (de Noronha et al., 2005; Westerberg et al., 2005; 
Gallego et al., 2006). Moreover, WASp-mediated actin poly-
merization controls phagocytic cup formation in monocytes, 
macrophages, and DCs (Leverrier et al., 2001; Tsuboi, 2007) 
Table 1. PDC numbers and MxA expression in WAS spleen
Case MxA score MxA pDCs Clinical score/autoimmunity
%
WAS#1 4 18.52 6.21 5/+
WAS#2 2 13.23 203.92 5/
WAS#3 3 7.99 154.98 5/
WAS#4 1 2.89 228.76 5/+
WAS#5 4 19.02 50.40 3/
WAS#6 2 1.03 93.71 3/
WAS#7 4 13.95 323.48 5/+
WAS#8 4 13.61 8.68 5/+
Mean (±SD) 3 11.28 (±6.7) 133.8 (±113.9)
CTR#1 3 14.44 131.15
CTR#2 1 0.47 578.25
CTR#3 2 1.6 202.63
CTR#4 2 0.15 223.00
CTR#5 2 4.21 NV
CTR#6 4 25.29 202.63
CTR#7 2 10.24 156.26
CTR#8 2 0.61 62.95
CTR#9 ne ne 83.21
CTR#10 3 20.48 43.80
Mean (±SD) 2.3 7.12 (±9.5) 187.10 (±160.30)
ne = not evaluable. MxA is expressed as the percentage of reactivity of the spleen area. pDCs are expressed as BDCA-2+ cells/mm2spleen area. Absolute pDC count and MxA 
expression were quantified on spleen sections of WAS patients. The MxA score was evaluated by counting the percentage of MxA+ cells and expressed as a four-tier scale. 
MxA percentage of reactivity of the spleen area and BDCA-2+ cells/mm2 spleen area were evaluated automatically on digital slides as described in Materials and methods. 
Disease score is given according to the classification reported previously (Imai et al., 2004)
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(Fig. 1, E and F). Significantly, in three of these cases, elevated 
MxA expression correlates to the occurrence of autoimmu-
nity (Table 1). Several studies have shown that sera from SLE 
patients trigger pDCs activation and IFN- release (Vallin 
et al., 1999; Lövgren et al., 2004; Barrat et al., 2005). To test 
this hypothesis in WAS, we incubated pDCs isolated from 
healthy donors (HDs) with sera derived from WAS patients 
or HDs. As a control, we included sera from patients with 
SLE and juvenile idiopathic arthritis (JIA). We observed induc-
tion of low to moderate production of IFN- by WAS sera that 
was statistically significant as compared with HD sera and simi-
lar to the induction by SLE and JIA sera (Fig. 2 A). A second 
hallmark of type-I IFN–driven disease is the up-regulation 
of IFN- gene transcripts in peripheral blood (Baechler et al., 
2003, 2007; van der Pouw Kraan et al., 2007; Emamian et al., 
2009; van Baarsen et al., 2009; Pascual et al., 2010). We analyzed 
human autoimmune diseases, including systemic lupus eryth-
ematosus (SLE), Sjogren syndrome, and psoriasis (Blanco 
et al., 2001; Båve et al., 2005; Nestle et al., 2005; Gottenberg 
et al., 2006; Becker-Herman et al., 2011). In these diseases, 
uncontrolled pDC activation depends on triggering of TLR7/9 
by self–nucleic acid–containing immune complexes (Barrat 
et al., 2005), binding of self-DNA to antimicrobial peptides 
(Lande et al., 2007), and clustering of self-DNA within neu-
trophil extracellular traps (Garcia-Romo et al., 2011).
The most common autoimmune features that develop in 
a high proportion of WAS patients include hemolytic ane-
mia, vasculitis, renal disease, and arthritis (Humblet-Baron 
et al., 2007; Bosticardo et al., 2009). These symptoms par-
tially overlap with those commonly observed in type-I IFN–
driven diseases. Based on this, we hypothesized an involvement 
of the pDC–IFN- axis in promoting autoimmunity in 
WAS. We provide evidences in patients and the demonstra-
tion in a mouse model that WASp deficiency in pDCs con-
trols activation of IFN-I genes contributing to autoimmune 
phenomena in WAS.
RESULTS
Frequency of pDCs and expression of type-I  
IFN–inducible genes in WAS patients
Dysregulated production of type-I IFN by pDCs repre-
sents a crucial step in the pathogenesis of autoimmune dis-
eases such as SLE, Sjogren syndrome, and psoriasis. Some 
typical features of these diseases, such as skin lesions, arthritis, 
renal diseases, and cutaneous vasculitis, are also present in a 
proportion of WAS patients. Moreover, autoantibodies that 
are known to convert self–nucleic acid into potent triggers of 
pDCs are abundant in a murine model of WAS deficiency 
and are also detected in a proportion of WAS patients (Dupuis-
Girod et al., 2003; Meyer-Bahlburg et al., 2008; Trifari et al., 
2010; Becker-Herman et al., 2011; Bosticardo et al., 2011). 
To investigate a possible contribution of altered pDC ho-
meostasis to the pathophysiology of WAS, we first analyzed 
spleen sections and peripheral blood of WAS patients. We 
previously reported a general depletion of the splenic white 
pulp in WAS spleen. However, this analysis was limited to 
lymphoid cell populations with no data on the occurrence 
and distribution of pDCs (Vermi et al., 1999). The avail-
ability of an anti–BDCA-2 capable to specifically identify 
human pDC on fixed tissues (Vermi et al., 2011) allowed us to 
analyze this cellular population of archival samples. Histolog-
ical analysis of WAS spleen sections detected variable num-
bers of BDCA-2+ cells showing a typical pDCs morphology 
and a regular distribution in the T cell area (Table 1 and 
Fig. 1, A–D). The mean number of pDCs in WAS spleen 
was comparable to control cases (133.7 vs. 183.6; P = 0.35) 
with two cases in which pDCs were almost absent (Fig. 1 G 
and Table 1). As a surrogate marker of type-I IFN produc-
tion, we directly assessed the protein level of myxovirus 
resistance protein A (MxA) on human spleen by immuno-
histochemistry. Interestingly, we detected an elevated ex-
pression of MxA (score ≥ 3) in five out of eight WAS patients 
Figure 1. Characterization of pDCs cells in spleen and peripheral 
blood of WAS patients. Spleen sections are obtained from WAS patients 
(A–E) and HDs (F) and stained for BDCA-2+ (A–D, brown), CD3 (D, blue), 
and MxA (E and F). Similarly to control cases, the spleen content of  
BDCA-2+ cells in WAS patients is extremely variable (WAS#2 in A, WAS#1 in  
B; G). BDCA-2+ cells show a typical PDC morphology (WAS#2 in C) and 
are regularly distributed mainly in T cell area (WAS#2 in D). E and F illus-
trate two cases of MxA score 4 (WAS#1) and score 2 (HD#2). Bars:  
(A, B, and D–F) 200 µm; (C) 33 µm. (G) The number of pDCs (CD303+ cells) 
in spleen sections was quantified automatically as described in Materials 
and methods. Horizontal bars indicate the mean value.
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evaluated by ELISA by the percentage of pDCs in each sam-
ple (Fig. 2 E). We found that the relative IFN- production 
by WAS patients was significantly higher compared with 
HDs (Fig. 2 E). Overall these data strongly suggest that the 
pDC–IFN- axis can be altered in WAS patients, thus con-
tributing to pathogenesis of autoimmune manifestations.
Constitutive activation and spontaneous  
IFN- release by WASp-deficient pDCs
To better understand the role of WASp in pDC, we moved 
to study a mouse model of WAS. Mice knocked out for WASp 
protein expression (WKO mice) present circulating autoan-
tibodies and develop spontaneous colitis and proliferative glo-
merulonephritis with immune complex deposition (Snapper 
et al., 1998; Humblet-Baron et al., 2007; Nikolov et al., 2010; 
Shimizu et al., 2012). Mutant mice also show infiltrates of 
B, T, and DCs in salivary glands, a feature commonly observed 
in mice models of Lupus and Sjogren Syndrome, and a 
moderate proteinuria index indicative of renal damage (not 
depicted; Humphreys-Beher, 1996; Fleck et al., 1998).
the expression of type-I IFN genes and IFN-–inducible 
targets (chosen among those found overexpressed in SLE 
patients) in a cohort of seven WAS patients with a clinical 
score of 4–5. Notably, we observed increased expression of 
IFN- genes in six of seven patients analyzed (Fig. 2 B). 
Moreover, the mean expression levels of five type-I IFN–
induced genes were significantly higher in this cohort of 
patients compared with age-matched HDs (Fig. 2 C). Next, 
we examined the frequency and responsiveness of the pDC 
compartment in PBMCs. In keeping with previous observa-
tions in SLE (Blomberg et al., 2003; Migita et al., 2005; Kwok 
et al., 2008b), we found a reduction in the frequency of pDCs 
in the PBMC of 15 pediatric WAS patients with a severe 
clinical score (3–5, described by Zhu et al., 1997) as compared 
with HDs (Fig. 2 D). Next we evaluated the capacity of WAS 
pDCs to produce IFN- in response to an agonist of TLR9. 
We stimulated total PBMCs using a pDC-specific TLR9 
ligand, CpG ODN2216. Since pDC frequency was different 
among WAS patients and HDs, we calculated the relative 
IFN- production dividing the absolute IFN- production 
Figure 2. Characterization of pDCs in 
peripheral blood of WAS patients.  
(A) IFN- induction in pDCs by serum from WAS 
patients. pDCs isolated from HDs were incubated 
with 50% serum from WAS, SLE, JIA patients, 
or HDs for 24 h. IFN- in supernatant was 
measured by ELISA. Values of IFN- super-
natants were subtracted from the values of  
IFN- in corresponding sera assayed in parallel 
without cells. Horizontal bars indicate the 
mean value. Data were analyzed with Mann-
Whitney test. *, P < 0.05; **, P < 0.01.  
(B and C) mRNA was extracted from PBMCs of 
seven WAS patients and five HDs. Data show 
expression of three IFN- transcripts (B) and 
five type-I IFN–inducible genes (C). Horizontal 
bars indicate the mean value. Horizontal 
dashed line indicates the normalized HD mean 
value. (D) The percentage of pDCs in PBMCs 
of 15 pediatric WAS patients and 10 age-
matched HDs was calculated by dividing the 
number of lineage-negative/BDCA-2+/CD4+ 
cells by the number of total live cells. Hori-
zontal bars indicate mean values. (E) Relative 
IFN- production by PBMCs from five WAS 
patients and eight HDs 24 h after stimulation 
with CpG ODN2216. Relative IFN- produc-
tion was calculated by dividing CpG 
ODN2216-induced IFN- production by the 
percentage of pDCs. Adult patient is indicated 
by #. ELISA and real-time PCR data were ana-
lyzed with Mann-Whitney test. *, P < 0.05;  
**, P < 0.01.
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Figure 3. Analysis of the pDC compartment in WASp-deficient mice. (A) Frequency and absolute numbers of pDCs in adult WKO mice. FACS dot 
plots show pDCs gating strategies, and numbers in quadrants refer to percentage of PDCA-1+/Siglec-H+/B220+ cells. Graphs show frequency and absolute 
number of pDCs in the spleen and LN of WT and WKO animals. n = 8–11 mice per group from three independent experiments. (B) Proliferation of pDCs  
in vivo. WT and WKO adult mice were fed BrdU in the drinking water for 7 d. Representative FACS plots showing the percentages of BrdU+ pDCs in spleen, 
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LN, and BM. Results are from two experiments with four mice per group. (C) The expression of maturation markers (CD86, CD40, and MHC-II) was mea-
sured by FACS on pDCs in different organs. The mean fluorescence intensity (MFI) in individual mice is indicated. Data are representative of two experi-
ments (n = 4–8 mice per group) of four performed. (D) The levels of IFN- and IL-6 in the sera of untreated mice were evaluated by ELISA. n = 13–14 WT 
mice and 13–19 WKO mice. (E) Data show the relative expression of Ifna4 mRNA in pDCs isolated from the spleen and LN of WT and WKO mice. CTs 
were obtained by normalizing target gene to the housekeeping -actin. Values are shown as the 2CT × 103. n = 4 mice per group in at least four inde-
pendent experiments. (F) WT and WKO splenic pDCs were plated at 3 × 105/well and the spontaneous release of IFN- was measured by ELISA 24 h later. 
Data are from three independent experiments, each with six mice per group. A–C, Mann-Whitney test; D–F, Student’s t test; error bars indicate SEM.  
*, P < 0.05; **, P < 0.01; ***, P < 0.001.
 
We first analyzed the pDC compartment in WKO mice. 
Conversely to patients, we found that the frequency and ab-
solute numbers of PDCA-1+/Siglec-H+/B220+ cells were 
higher both in spleen and LNs of WKO mice (Fig. 3 A). To 
understand the origin of increased cell numbers, we per-
formed an in vivo BrdU labeling experiment by feeding WT 
and WKO mice for 7 d with BrdU in the drinking water. 
The number of labeled pDCs in the spleen, LNs, and BM 
was twice as much in WKO than in WT animals, indicating 
an enhanced turnover rate (Fig. 3 B). WKO pDCs express 
significantly higher levels of MHC class-II and costimulatory 
molecules (CD40 and CD86) in spleen, LNs, and blood, fur-
ther indicating a state of constitutive activation (Fig. 3 C). To 
examine whether chronically activated pDCs may be a source 
of elevated IFN-, we analyzed the sera of WT and WKO 
mice. As shown in Fig. 3 D, in the absence of any in vivo 
stimulation, significantly higher levels of IFN- were de-
tected in the serum of WKO than of WT mice; in contrast, 
levels of the inflammatory cytokine IL-6 were similar in both 
groups of mice. Circulating IFN- at steady state is not 
simply a consequence of increased pDC numbers, as mRNA 
extracted from equal numbers of splenic and LN pDCs con-
firmed the presence of IFN- transcripts only in WKO pDCs 
(Fig. 3 E). Moderate levels of IFN- protein were also de-
tected in the supernatant of WKO splenic pDCs  incubated 
ex vivo in medium without stimuli (Fig. 3 F). Thus, pDCs in 
WASp-deficient animals are spontaneously activated and con-
stitutively secrete detectable amounts of type-I IFN.
WKO pDCs develop a selective exhaustion  
of the TLR9–IFN- pathway
To further examine functional abnormalities in WASp-deficient 
pDCs, we evaluated their response to exogenous TLR ago-
nists. WT and WKO mice were challenged intravenously with 
CpG-A-DOTAP, which induces secretion of high levels of 
type-I IFN by pDCs in the spleen. In WT mice, the levels of 
IFN- peaked at 6 h after injection, whereas we detected a 
significantly lower IFN- production in WKO mice at all time 
points tested (Fig. 4 A). The levels of IL-6 and IL-12p40 were 
comparable in the two genotypes (Fig. 4 A). Similarly, intra-
cellular staining of splenic pDCs showed increasing numbers 
of IFN-–producing pDCs at 2.5 and 6 h after injection in 
WT mice, whereas lower percentages of positive cells were 
detected in WKO mice at all time points (Fig. 4 B). We next 
evaluated the production of type-I IFN and inflammatory cyto-
kines in cells stimulated ex vivo with agonists of TLR9 and 
TLR7. We used two agonists of TLR9: multimeric CpG-A, 
which induces robust IRF-7–mediated transcription of IFN- 
genes and little proinflammatory cytokines, and CpG-B, which 
induces preferentially inflammatory cytokines. As an agonist 
of TLR7, we used Imiquimod (R837; Honda et al., 2005). As 
expected, multimeric CpG-A, R837, and, to a lower extent, 
CpG-B induced IFN- gene transcription and protein secre-
tion in WT pDCs (Fig. 4 C). In contrast, IFN- production 
was strongly impaired in WKO pDCs in response to agonist 
of TLR7 and TLR9, both at the transcriptional and protein 
level. Release of inflammatory cytokines varied depending on 
the agonist used but was overall similar in WT and WKO pDCs 
(Fig. 4, C and D). In sum, these data show that pDCs in adult 
WKO mice are hyporesponsive in terms of IFN- while 
maintaining intact the capacity to produce inflammatory cyto-
kines upon TLR7/9 triggering. This is consistent with the 
fact that chronically activated pDCs become refractory to fur-
ther TLR challenge (Pau et al., 2012).
WKO pDCs are intrinsically more responsive to TLR9 triggering
We next investigated the mechanism of altered pDC func-
tions. First, we tested whether spontaneous pDC activation 
may depend on the presence of endogenous pDC activators 
in sera, as seen in WAS patients. We confirmed that serum 
from adult WKO contains autoantibodies (Humblet-Baron 
et al., 2007; Becker-Herman et al., 2011; Recher et al., 2012). 
As shown in Fig. 5 (A and B), we found anti-nuclear and 
anti–double-stranded (ds) DNA antibodies in adult WKO 
mice that are absent in younger animals (3 wk; Fig. 5, A and B). 
Stimulation of pDCs with sera from adult WKO mice (6–12 
wk), but not with sera from adult WT mice, induced IFN- 
gene transcription and release of little but detectable amounts 
of IFN- in the cell culture supernatant. Sera from young 
WKO mice failed to induce IFN- secretion. Moreover, the 
IFN-–inducing capacity of WKO sera was reduced upon pre-
treatment with DNase (Fig. 5 D). Thus, immune complexes 
of autoantibodies and self–nucleic acid may constitute an 
endogenous trigger of pDC activation in vivo in WAS mice. 
Activation by endogenous factors would explain, at least in 
part, chronic pDC activation and exhaustion of the IFN- 
pathway, similarly to what has been described in SLE (Ito 
et al., 2006; Kwok et al., 2008a).
However, a second not mutually exclusive hypothesis is 
that cell intrinsic factors lower the threshold for pDC acti-
vation. Consistent with this, WKO B cells were recently 
shown to be intrinsically hyperresponsive to TLR9 triggering 
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CpG-A was also reflected in slightly enhanced IL-6 produc-
tion that, despite being only weakly induced by this agonist, 
was augmented in WKO cells. TNF production in the cell 
culture supernatant was comparable between WT and WKO; 
however, intracellular staining at early time points revealed a 
higher fraction of cells positive for both IFN-I and TNF in 
(Becker-Herman et al., 2011; Recher et al., 2012). To address 
this possibility, we first examined the responsiveness of naive 
pDCs isolated from young (3 wk old) mice with undetectable 
anti-nuclear antibodies. We found that CpG-A, but not 
R837, induced a significantly enhanced production of IFN- 
by WKO young pDCs (Fig. 6 A). Hyperresponsiveness to 
Figure 4. Progressive exhaustion of the TLR9/IFN- in WKO mice. (A) WT and WKO adult (>6 wk) mice were injected intravenously with 10 µg 
CpG-A in complex with the cationic lipid DOTAP. Serum levels of IFN-, IL-6, and IL-12p40 were measured by ELISA at 2, 6, 10, and 24 h after injection. n = 4–9 
mice per group in three independent experiments. (B) Dot plots showing IFN- intracellular staining in the spleen of WT and WKO mice isolated at dif-
ferent time points after injection. Numbers represents the percentage of cells in the respective quadrant. Data are representative of one of three experi-
ments performed each with three mice per group. (C) Gene transcription and protein release in splenic pDCs sorted from WT and WKO adult mice. Cells 
were stimulated ex vivo with CpG-A, CpG-B, and R837 (15 µg/ml). The relative expression of Ifna4 transcripts was evaluated by qRT–PCR at 4 and 24 h. 
The target mRNA was normalized to -actin mRNA. Values are shown as the 2CT × 103. The levels of IFN- (C, right), IL-6, and IL-12p40 (D) were measured 
in cell culture supernatants after 16 h. Results are representative of four (CpG-A and CpG-B in C) and three (R837 in C and D) independent experiments. 
A, Mann-Whitney test; C and D, Student’s t test; error bars indicate SEM. *, P < 0.05; **, P < 0.01; ***, P < 0.001.
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WKO pDCs stimulated by CpG-A (Fig. 6 B). CpG-B and 
R837 induced equal levels of IFN- and cytokines in the 
two groups. Notably, young WKO pDCs responded more 
vigorously than young WT pDCs to stimulation with sera 
derived from adult WKO animals (Fig. 6 C). Collectively, 
these data strongly suggest that naive WKO pDCs are hyper-
responsive, especially in terms of IFN- production, to mul-
timeric TLR9 agonists (CpG-A and DNA immune complexes 
in sera). To fully establish that WASp controls activation of 
the TLR9–IFN- pathway and to demonstrate that pDC 
dysregulation is cell autonomous, we treated pDCs with 
siRNA oligos that target WASp. WT pDCs treated with a 
Was-specific siRNA showed a 70% reduction in protein 
expression compared with cells treated with a control siRNA 
(Fig. 6 D). CpG-A stimulation of WASp-depleted cells 
induced significantly higher IFN- and slightly increased 
IL-6, as compared with cells treated with the control siRNA, 
whereas inflammatory cytokines induced by CpG-B were 
comparable (Fig. 6 D). In a parallel experiment of gene de-
pletion in conventional BM-derived DCs, we observed no 
differences in the levels of IL-6 and IL12p40 produced after 
stimulation with CpG-B (Fig. 6 E). Thus, in a setting that 
completely excludes environmental factors, full expression of 
WASp is required to control activation of the TLR9 pathway 
intrinsically in pDCs. Interestingly, interfering with actin po-
lymerization by means of two different actin inhibitors, cyto-
chalasin-d and latrunculin-A, significantly enhanced IFN- 
and slightly enhanced IL-6 release upon CpG-A triggering. 
The release of proinflammatory cytokines upon CpG-B treat-
ment was not affected (Fig. 6, F and G). Cytokine production 
by conventional DCs (cDCs) was also not modified by cyto-
chalasin-d treatment (Fig. 6 H). Therefore, we conclude that 
in a cell-intrinsic fashion, WASp-mediated actin dynamics 
controls activation of TLR9 signaling upon internalization of 
multimeric TLR9 ligands.
Altered endocytic pathway and CpG-A  
accumulation in WASp null pDCs
We next examined the cell biological basis of increased 
IFN- production in WASp null pDCs. The unique ability 
of pDCs to produce large amounts of type-I IFN depends 
on spatiotemporal regulation of ligand/receptor trafficking 
within the endocytic pathway. It has been widely documented 
that retention of large DNA aggregates into early endosomes 
(EE) and trafficking to lysosome-related organelles are two 
steps that control robust activation of IFN- genes (Honda 
et al., 2005; Guiducci et al., 2006; Sasai and Iwasaki, 2011). 
As recent reports showed that nucleating promoting factors 
like the Arp2/3 complex (a downstream WASp effector), 
Figure 5. WKO serum induces IFN- secretion by pDCs. (A) The 
presence of IgG anti-dsDNA autoantibodies in sera was analyzed by 
immunostaining of NIH3T3 cells. Diluted sera from control (WT), WKO 
(>6 mo), and young WKO (3 wk) mice were incubated with NIH3T3 cells, 
and the anti-nuclear reactivity was detected using FITC-conjugated anti-IgG 
antibody (right). Nuclei were visualized by DAPI staining (left). Represen-
tative images from one out of four sera tested/group are shown. Bar, 36 µM. 
(B) Levels of IgG anti-dsDNA autoantibodies were evaluated by ELISA in 
sera (1:800 dilution) from 3-wk-old, 3–4-mo-old, and 6–7-mo-old WKO 
mice. As positive and negative controls, SLE-prone NZW/NZB F1 mice  
(6 mo old) and WT mice (4–7 mo old) were used, respectively. Each dot 
represents an individual animal. Horizontal bars indicate medians.  
(C) 3.5 × 105 WT BM–derived pDCs (BM-pDCs) were stimulated with sera 
from WT or WKO mice for 7 h. Relative expression of Ifna4 transcripts 
were evaluated by qRT-PCR. Data are representative of sera from n = 4 
mice per group in two independent experiments. (D) 3.5 × 105 WT BM-
pDCs were stimulated with sera from the indicated groups of animals 
(pooled sera of four animals per group) treated or not with DNase I.  
Secretion of IFN- was measured by ELISA at 24 h. Data are expressed as 
the values in experimental wells subtracted of the values in control wells 
(dilutions of sera without cells). B and D, Mann-Whitney test; error bars 
indicate SEM. *, P < 0.05.
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Figure 6. Cell-intrinsic role of WASp-mediated actin dynamics in limiting IFN- production in pDCs. (A) Responses to TLR9 and TLR7 agonists in 
naive pDCs from young WKO mice. 3 × 105 pDCs isolated from the spleen of young (3 wk) WT or WKO mice were stimulated ex vivo with 10 µg/ml CpG-A 
or CpG-B and 5 µg/ml R837. Bars show IFN-, IL-6, and TNF protein levels determined by ELISA in cell culture supernatant. Results are from two (R837) to 
five (CpG-A and CpG-B) independent experiments each with six mice per group. (B) pDCs were stimulated with 20 µg/ml CpG-A for 5 h in the presence of 
brefeldin A. Intracellular staining was performed with antibodies against IFN- and TNF. The plots are from one representative experiment of three per-
formed. (C) Splenic pDCs from young WT or WKO mice were incubated with sera from WT (n = 4) or WKO (n = 4) adult mice. Data show the levels of IFN- 
in cell culture supernatants subtracted of the values in control wells without cells. Data are representative of two experiments with six mice per group.  
(D and E) BM-pDCs or BM-cDCs were nucleofected with siRNA control (si-irr) or WASp-specific (si-WASp) RNA oligos. (D) 3 × 105 control or WASp-silenced 
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BM-pDCs were stimulated with 15 µg/ml CpG-A or CpG-B. IFN- and IL-6 protein levels were determined by ELISA. Results are from four experiments.  
(E) 3 × 105 control or WASp-silenced BM-cDCs were stimulated with 15 µg/ml CpG-B. IL-12p40 and IL-6 protein levels were determined by ELISA. Results 
are representative of three experiments. (F) 3 × 105 BM-pDCs were preincubated with 1 µg/ml cytochalasin-d (Cyto-d), 0.1 µg/ml latrunculin-A or control 
medium, washed and stimulated with 5 µg/ml CpG-A for 5 h. Bars show concentrations of IFN- and IL-6 protein in cell culture supernatants. Data are 
representative of two (latrunculin-A) to six (cytochalasin-d) independent experiments. Levels of IL-6 (G) and IL-12p40 (H) induced by CpG-B in Cyto-D–treated 
pDCs and Cyto-D–treated cDCs upon stimulation with 15 µg/ml CpG-A and CpG-B, respectively. One representative experiment out of three with similar 
results is shown. A, D, and E, Student’s t test; F, Mann-Whitney test; error bars indicate SEM. *, P < 0.05; **, P < 0.01; ***, P < 0.001.
 
WASH, and cortactin are involved in EE fission and matura-
tion into lysosomes (Derivery et al., 2009; Ohashi et al., 
2011), we postulated that WASp might be involved in regu-
lation of pDC activation by controlling delivery of TLR9 
ligands within the endocytic pathway. To address this ques-
tion, we first examined actin reorganization and WASp acti-
vation in WT pDCs. In agreement with previous observations 
in macrophages and myeloid DCs (Sanjuan et al., 2006), we 
found that CpG-A induces phosphorylation of Src kinases and 
actin regulatory proteins such as paxillin and pyk2 (Fig. 7 A). 
Notably, stimulation with CpG-A induced a rapid increase in 
WASp phosphorylation, a mechanism which was shown to 
be essential for WASp functions in several model systems 
but which has not been previously reported to be associated 
to TLR9 signaling (Fig. 7 B). Immunolabeling of WASp in 
pDCs was weak but specific and revealed a shifting from a 
diffuse cytoplasmic distribution in resting pDCs to accumu-
lation of WASp in patches overlapping with EE upon CpG-
A stimulation, suggesting that WASp is involved in remodeling 
of endosomal actin during pDCs activation by TLR9 ago-
nists (Fig. 7 C).
Next, we analyzed by confocal microscopy the fate of in-
ternalized CpG-A labeled with FITC in splenic pDCs isolated 
from young WT or WKO animals. EE in nonstimulated WT 
pDCs appeared as well defined rounded vesicles (mean EE 
volume = 3.3 µm3 ± 3.3 SD) distributed uniformly (Fig. 8 A). 
In contrast, EE were often clustered in larger vesicles at one 
pole of the cells in resting WKO pDCs (mean EE volume = 
5.24 µm3 ± 6 SD). Stimulation with CpG-A FITC induced 
clustering of EE vesicles in areas of CpG-A uptake in both WT 
and WKO cells, resulting in an increase of EE volumes that 
was slightly higher in WKO cells. Remarkably, CpG-A vesi-
cles inside WKO cells were larger and often displayed a tubular 
shape (Fig. 8, A and C). Quantitative analysis on 3D recon-
structed images showed that intracellular CpG-A vesicles 
have significantly larger volumes in WKO than in WT pDCs 
(Fig. 8 A). To establish that actin remodeling driven by WASp 
controls the compartmentalization of TLR9 ligands in pDCs, 
we analyzed CpG-A vesicles in cells depleted of WASp expres-
sion by siRNA or treated with Cyto-D. The mean volume of 
the CpG-A–containing compartments was increased in both 
conditions, indicating that enhanced accumulation of TLR9 
ligands is linked to stronger activation of IFN- genes (Fig. 8 B). 
To better understand the nature of the CpG-A containing 
compartment, we quantified the colocalization of CpG-A FITC 
with markers of EE (EEA-1) and lysosomes (LAMP-1). At 1 h 
Figure 7. CpG-A induces tyrosine phos-
phorylation of WASp and its localization 
in EE. (A) WT BM-pDCs were stimulated with 
20 µg/ml CpG-A and whole cell lysates were 
Western blotted with anti-phospho paxillin, 
anti-phospho Pyk2, and anti-phospho Src 
antibodies. (B) WT BM-pDCs were lysed after 
the indicated times of stimulation with CpG-A. 
WASp was immunoprecipitated from the cell 
lysates and the anti-WASp immunoprecipi-
tates were Western blotted with anti total 
phospho-tyrosine and anti-WASp antibodies. 
(C) WT or WKO splenic pDC were labeled with 
antibodies against WASp to assess staining 
specificity (bars, far left panels, 33 µm).  
WT splenic pDCs from adult mice were left  
untreated or stimulated with CpG-A for 30 min, 
fixed, and labeled with antibodies against 
WASp and the EE marker EEA-1. Representa-
tive single confocal z-planes (middle) are 
shown. Bars, 3 µm. (D) The index of colocal-
ization (Pearson’s coefficient) between WASp 
and EEA-1 staining was measured on 9 and 10 
resting and stimulated cells, respectively. Red 
horizontal bars indicate the median. Mann-
Whitney test.
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Figure 8. WASp controls CpG-A accumulation and EE size in pDCs. (A) Splenic pDCs from young WT and WKO mice were stimulated with 20 µg/ml 
CpG-A FITC for 30 min or left untreated (NS). Shown are representative confocal images of CpG-A and EEA-1 merged with DIC images. The quantification 
of EE volumes and CpG-A volumes on 3D reconstructed z-sections is shown on the right. For EE volumes, n = 85, 19, 63, and 25 for WT(NS), WT(CpG-A), 
WKO(NS), and WKO(CpG-A), respectively. Mean and SEM are indicated, Mann-Whitney test. For CpG-A volumes, n = 74 and n = 77 cells were analyzed in 
WT and WKO, respectively. Horizontal bars show mean values. ***, P = 0.0008, Mann-Whitney. (B) Splenic WT pDCs were pretreated with cytochalasin-d 
(or control medium) for 30 min, washed, and exposed to CpG-A FITC for 30 min. Confocal images show representative example of CpG-A and EEA-1 
staining merged with DIC images. The volume of intracellular CpG-A vesicles was quantified on >30 cells per condition. Bars show mean values, P = 0.034, 
Mann-Whitney. (C) BM-PDCs treated with control or WASp-specific siRNA (si-IRR and si-WASp) were incubated with CpG-A-cy5 and immunostained 
with anti–EEA-1 antibodies. Representative single confocal planes are shown. The plot shows the quantification of CpG-A containing vesicles measured 
on 3D reconstructed images. Data were collected from 50 si-irr– and 50 si-WASp–treated cells. Horizontal bars show mean values. **, P = 0.0021, Mann-
Whitney test. (D) Splenic pDCs isolated from young mice were incubated with 20 µg/ml CpG-A FITC for 1 h. Confocal images of CpG-A and EEA-1 (left) 
and LAMP-1 (right) staining merged with DIC images are shown. The graph represents Pearson’s correlation coefficients that were calculated for CpG-A 
and EEA-1 or CpG-A and LAMP-1 on 3D reconstituted z-sections. Data are from n = 74 WT and n = 41 WKO cells for EEA-1 (**, P = 0.0037), and from  
366 Role of WASp in pDCs | Prete et al.
any stimulation, splenic WKO cDCs expressed significantly 
higher levels of maturation markers (CD40 and CD86) than 
WT cDCs, indicating a state of chronic activation. Expression 
in DKO cDCs was intermediate between WT and WKO, 
showing an almost complete rescue of spontaneous matura-
tion. Moreover MHC-I expression was high in WKO cDCs 
but returned to WT level in cDCs isolated from DKO mice. 
Next, we stimulated cDCs with CpG-B or LPS to measure 
the production of proinflammatory cytokines. WKO cDCs 
produced increased levels of TNF, IL-12p40, and IL-6 as 
compared with WT cells. In contrast, secretion by DKO cells 
was significantly lower than in WKO cells and, for IL-6, even 
lower than in WT cells (Fig. 9 D). Thus, excessive maturation 
and responsiveness toTLR4 and TLR9 in WKO cDCs depend 
on engagement of IFNAR. Secretion of B cell activating 
factor (BAFF) by IFN-–activated cDCs is a major mecha-
nism by which DCs may amplify production of autoantibod-
ies (Litinskiy et al., 2002; Cancro et al., 2009). The levels of 
BAFF in sera of WKO animals were indeed significantly higher 
than in WT mice, whereas they were completely rescued in 
DKO mice (Fig. 9 E). However, despite rescued BAFF levels, 
DKO mice still contained elevated anti-dsDNA antibodies, 
suggesting that cell-intrinsic B cell defects (Becker-Herman 
et al., 2011; Recher et al., 2012) are dominant over the con-
tribution of the type-I IFN–BAFF axis (Fig. 9 F). Based on these 
data, we conclude that type-I IFN signaling in WAS pro-
motes excessive activation of DCs and contributes to the de-
velopment of autoimmune manifestations.
DISCUSSION
The mechanisms that limit unrestrained activation of innate 
immune cells upon ligation of pattern recognition receptors 
are of great interest, as it is increasingly recognized that failure 
to prevent excessive activation leads to chronic inflammation 
and autoimmunity. This work provides the first description 
of the role of WASp in pDCs, a crucial subset of innate im-
mune cells specialized in secretion of type-I IFN. We show 
that type-I IFN production is negatively regulated by WASp-
dependent actin dynamics, both indirectly through cell ex-
trinsic mechanisms and in a cell autonomous fashion. The 
combination of extrinsic and intrinsic cellular mechanisms 
leads to chronic pDC activation and spontaneous release of 
IFN- that is involved in autoimmune disease. These find-
ings provide a new important clue to understand the devel-
opment of autoimmune phenomena in WAS and suggest the 
inclusion of the syndrome in the list of type-I IFN diseases.
pDCs are specialized in producing high levels of type-I IFNs 
upon recognition of foreign nucleic acid derived from endo-
cytosed pathogens. In several type-I IFN diseases (SLE, Sjorgen, 
and psoriasis), unwanted pDC activation by self-nucleic acid 
after uptake, CpG-A showed higher association with EE than 
with lysosome markers in both WT and WKO cells. However 
the index of CpG-A/EE colocalization was higher in WKO 
cells. Merging with lysosome markers was limited in WT 
pDCs (mean Pearson’s coefficient = 0.18 ± 0.018), whereas it 
was significantly higher in WKO pDCs (mean Pearson’s co-
efficient = 0.315 ± 0.02; Fig. 8 C). These data indicate that 
WKO pDCs accumulate larger amounts of intracellular CpG-A 
that are rapidly translocated to TLR9 signaling compartments. 
We next quantified the nuclear translocation of IRF-7 in cells 
stimulated with CpG-A. IRF-7 staining was confined in the 
cytoplasm of nonstimulated cells and begun to accumulate in 
the nucleus at 2 h after activation. Quantitative analysis of 
nuclear/cytoplasmic IRF-7 fluorescence intensity revealed a 
higher ratio in stimulated WKO pDCs, indicating stronger 
nuclear recruitment. Thus, increased IFN- production in 
WKO pDC is a result of enhanced signaling through the TLR9–
IRF-7 axis. Collectively, we conclude that lack of WASp in 
pDCs causes accumulation of large aggregates of multimeric 
TLR-9 ligands that rapidly traffic within the endocytic path-
way leading to increased IRF-7 activation.
Rescue of autoimmune manifestations in WASp null mice 
on an IFNAR-deficient background
Finally, we directly examined whether dysregulated type-I 
IFN production plays a role in the pathogenesis of WAS auto-
immune phenomena. To this purpose, we backcrossed WKO 
mice to mice lacking a functional IFN-/ receptor (Prinz 
et al., 2008), referred to as DKO mice, hereafter. Ablation 
of type-I IFN signaling in WKO mice caused a significant 
reduction of splenomegaly and amelioration of colitis. As 
shown in Fig. 9 A, the total cellularity and spleen weight 
were increased in adult WKO mice with respect to WT 
mice, whereas they were comparable between WT and DKO 
mice. Consistent with previous reports (Snapper et al., 1998), 
4-mo-old WKO mice develop colitis characterized by a dense 
mucosal T cell infiltration as measured on CD3-stained sec-
tions (18.25 CD3+ cells/high power field [HPF] for WT vs. 
58.25 CD3+ cells/HPF for WKO, P < 0.0001). In DKO, the 
density of infiltrating T cells was intermediate between WT 
and WKO (31.5 CD3+ cells/HPF) but still significantly dif-
ferent from the WT group (P < 001). Similarly, infiltrates of 
B and T cells in salivary glands were increased in WKO but 
almost absent in DKO animals (unpublished data).
Constitutive pDC activation and production of type-I 
IFN contribute to breach of peripheral tolerance through 
activation of cDC, boosting their antigen-presenting capacity 
and secretion of proinflammatory cytokines (Blanco et al., 
2001; Ding et al., 2006; Agrawal et al., 2009). We examined 
maturation and cytokine secretion in cDCs. In the absence of 
n = 116 WT and n = 72 WKO cells for LAMP-1 (***, P = 0.0005, Mann-Whitney t test). Horizontal bars represent median. (E) Splenic pDCs from young mice 
were incubated with 10 µg/ml CpG-A for 2 h, fixed, and labeled with antibodies against IRF-7. Representative images are of resting and stimulated WT 
and WKO cells. The quantification shows the ratio between the mean fluorescence intensity in cytoplasm versus nucleus calculated on 4 and 25 resting 
and stimulated cells, respectively, in each group. Horizontal bars show mean values. **, P = 0.0017, Mann-Whitney test. Bars, 3 µm.
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Figure 9. Partial rescue of autoimmune disease in IFNAR/WASp double KO mice. (A) Representative spleens from 3-mo-old WT, WKO, and DKO 
mice. Graphs represent spleen wet weight (in grams) and total splenocytes counts (n = 7–10 animals per group). (B) Formalin-fixed sections of large 
bowel are from 4-mo-old WT (left), WKO (middle), and DKO (right) mice and stained for anti-CD3. Compared with WT, WKO, and, to a lesser extent, DKO, 
show increased mucosal infiltration of CD3+ T cells. Sections are counterstained with Mayer’s hematoxylin. Bar, 200 µm. (C) Mean fluorescence intensity 
(MFI) of CD86, CD40, and MHC-I expressed by cDC (CD11chi) at steady state were measured by FACS in spleens of WT, WKO, and DKO mice. Data are from 
three independent experiments, each with two to four mice per group. (D) 3 × 105 WT, WKO, and DKO BM-cDCs were incubated with increasing doses of 
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proliferation of autoreactive B cells and T cells (Jego et al., 
2003; Le Bon et al., 2006a,b). This is well illustrated in lupus-
prone mice models in which IFNAR deficiency invariably 
reduces the levels of autoantibodies (Santiago-Raber et al., 
2003; Agrawal et al., 2009). Intriguingly, WASp mice defi-
cient for IFNAR receptor, despite amelioration of others major 
autoimmune signs, still have elevated anti-dsDNA antibodies, 
indicating that both IFN-I–dependent and –independent path-
ways contribute to autoimmunity. Although further analyses 
are needed to characterize subclasses and specificity of auto-
antibodies in these mice, the data are consistent with a domi-
nant cell intrinsic break in the B cell compartment in WAS 
(Becker-Herman et al., 2011; Recher et al., 2012).
We have identified two mechanisms that contribute to 
unabated pDCs activation in WASp-deficient animals. First, sera 
of WKO adult mice can induce IFN- secretion, strongly sug-
gesting that self–nucleic acids, in complex with autoantibodies 
(Humblet-Baron et al., 2007; Nikolov et al., 2010), are con-
verted into pDCs inducers, similarly to what has been described 
in SLE (Barrat et al., 2005; Means et al., 2005). It is likely that 
other factors participate in pDC activation in WKO, given that 
inefficient clearance of dying cells by macrophages (Lorenzi 
et al., 2000) is a source of endogenous TLR9 agonist (Båve 
et al., 2000). Chronic pDC activation in WASp mice caused 
a selective exhaustion of the IFN- pathway. This selective 
effect may depend on consumption of specific factors in the 
Myd88–IRF-7 pathway or on the induction of negative reg-
ulators (Escoll et al., 2003). A similar inability of pDCs to make 
type-I IFN in response to a secondary challenge has already 
been described in the context of viral infections (Björck, 2004; 
Ito et al., 2006), in lupus-prone mice (Pau et al., 2012), and in 
SLE patients (Kwok et al., 2008a). Whether exhaustion of the 
IFN- pathway is playing a role in inefficient viral clearance 
in WKO mice (Strom et al., 2003; Andreansky et al., 2005) 
will be a subject of future studies and it is certainly an impor-
tant implication of our findings. Second and most compelling, 
we demonstrated with different approaches that WASp-deficient 
pDCs are inherently hyperresponsive to TLR9 triggering. 
Importantly, drug-induced inhibition of actin polymerization 
enhanced cytokine production, thus strengthening the no-
tion that WASp restrains excessive activation via its actin 
regulatory properties. TLR9 signals through the adaptor pro-
tein MyD88 to activate two distinct pathways, one leading to 
the transcription of proinflammatory cytokines via NF-B 
and the second leading to type-I IFN through IRF-7. Acti-
vation of these two different pathways depends on signaling 
from distinct endocytic organelles, with activation of IFN- 
requiring access of TLR9 to lysosome-like organelles (Honda 
et al., 2005; Sasai et al., 2010). Our functional studies show 
complexes has been recognized as a major pathogenetic mech-
anism (Vallin et al., 1999; Barrat et al., 2005; Gilliet and Lande, 
2008; Gilliet et al., 2008). In the mouse model of WASp 
deficiency, we observed multiple signs of pDC activation, in-
cluding an increased proliferation rate, higher expression of 
surface maturation markers, constitutive transcription of 
IFN- genes, and elevated levels of systemic IFN-. Many 
evidences in WAS patients support the conclusion that ele-
vated type-I IFN may contribute to disease pathogenesis. 
Analysis of gene expression on RNA isolated from PBMC 
of pediatric patients with a high clinical score showed up-
regulated expression of IFN- genes and of several type-I in-
ducible genes, as compared with normal donors, demonstrating 
exposure to elevated levels of this cytokine. Second, the sera 
from WAS patients, similarly to sera from SLE and JIA, in-
duced release of IFN- by normal pDCs. This indicates that 
the well documented pathogenic mechanism of chronic pDC 
triggering by endogenous factors is likely to operate also in 
WAS patients. In spite of this, we failed to detect consistent 
levels of IFN- in sera, except from one patient with overt 
autoimmunity (unpublished data). Analysis of expression of 
MxA by immunohistochemistry on spleen sections of affected 
young boys confirmed elevated expression of this major target 
of type-I IFN in secondary lymphoid organs. We also report 
a reduced frequency of pDCs in the peripheral blood of our 
cohort of pediatric WAS patients. In this respect, the discrep-
ancy with increased pDCs number observed in WKO mice 
may be explained by the exposure of WAS patients to re-
peated infections and corticosteroid treatment, two factors 
which can contribute to pDCs depletion (Duan et al., 2004; 
Kanto et al., 2004; Altfeld et al., 2011). Of note, total PBMC 
from WAS patients showed an increased IFN- secretion 
when challenged with TLR9 agonist. This finding is consis-
tent with our observations in WASp null mouse pDCs (young 
prediseased mice and WASp silenced pDCs), strongly sup-
porting that pDCs are basically hyperresponsive. It may be 
that blood-derived pDCs in PBMC, as opposed to splenic pDCs 
in mice, are just generated and have not yet been exposed to 
endogenous triggers, maintaining their naive responsiveness.
Indeed, we demonstrated a role for type-I IFN in the 
initiation of autoimmunity. WASp null mice made resistant to 
type-I IFN have milder disease in terms of splenomegaly, coli-
tis, and salivary gland infiltrates. Our data suggest that IFN- 
signaling diverts DCs toward a proinflammatory phenotype, 
which may directly contribute to development of colitis by 
inhibiting T reg cell proliferation (Murai et al., 2009). Con-
sistent with this, a recent report showed a role for innate im-
mune cells in inducing colitis in WASp null mice (Nguyen 
et al., 2012). Type-I IFN may also have direct effects in promoting 
CpG-B (top) or LPS (bottom). The levels of TNF, IL-12p40, and IL-6 were measured by ELISA in 4-h cell culture supernatants. Data are from two indepen-
dent experiments, each with two to four mice per group. (E) The levels of BAFF were compared in the sera of WT (n = 10), WKO (n = 9), and DKO (n = 11) 
animals in absence of any prior stimulation. Error bars indicate SEM. Statistics were calculated by one-way ANOVA followed by Bonferroni’s post hoc test. 
(F) Levels of IgG anti-dsDNA autoantibodies were evaluated by ELISA in sera from WT, WKO, and DKO mice at 2 and 4 mo of age (n = 4 mice per group). 
Horizontal bars show median. *, P < 0.05; **, P < 0.01; ***, P < 0.001.
 
JEM Vol. 210, No. 2 
Article
369
that WKO pDCs isolated from young animals have a lower 
activation threshold for both pathways, but the effect on 
IFN- production is more pronounced. Moreover, hyperre-
sponsiveness is restricted to multimeric TLR9 agonists that 
were shown to be retained into endosomes during activation 
of the MyD88–IRF-7 pathway (Honda et al., 2005). Our 
imaging studies revealed that perturbing actin dynamics in 
pDCs (by different approaches) invariably causes an increase 
in the size of the CpG-A–containing vesicles and that CpG-A 
in WKO pDCs becomes associated to lysosomes more than 
in WT cells. Although we could not gain a dynamic picture 
of CpG-A trafficking in WKO pDCs, we propose that al-
tered actin dynamics cause a slower or diverted progression 
along the endocytic pathway that favors assembly of the signal-
ing cascade (especially the MyD88–IRF-7 branch, responsi-
ble for IFN- activation). Alternatively, WASp may be 
required for the docking of negative regulators of TLR9 sig-
naling. Indeed, recent studies illustrated the role of actin dur-
ing clathrin-mediated endocytosis (the pathway used by 
CpG-A to enter cells; Latz et al., 2004). WASp plays a central 
role in coordinating the action of several proteins, such as 
dynamin, myosins, membrane curvature proteins, cortactin, 
and intersectin, during the endocytic process (Cao et al., 
2003; Itoh et al., 2005; Kaksonen et al., 2005; Merrifield 
et al., 2005; Takenawa and Suetsugu, 2007). Therefore, lack of 
WASp in pDCs may inhibit correct vesicle scission/fission/
sorting, or indirectly perturb the coordinated action of the 
remaining proteins that compete with WASp for upstream 
activators or downstream effectors. Interestingly, depletion of 
cortactin and actin depolymerizing drugs were shown to 
induce endosome enlargement and tubulation similarly to 
what we observed in WKO cells (Itoh et al., 2005; Ohashi et al., 
2011). It would be interesting to evaluate whether the in-
creased responses to TLR9 triggering recently reported in WASp 
null B cells (Becker-Herman et al., 2011) are linked to similar 
alterations of the endocytic pathway. In conclusion, this study 
adds a new layer of complexity to our understanding of the 
pathophysiology of this disease and raises important consider-
ations about the treatment of patients with autoimmune phe-
nomena. Finally, the implications of this study go beyond the 
pathophysiology of WAS, introducing actin as a new 
player in the complex scenario of the negative regulation of 
IFN- production in pDCs.
MATERIALS AND METHODS
Patients and tissues. The occurrence, frequency, and distribution of 
PDC were studied on formalin-fixed paraffin-embedded spleen sections 
from patients affected by WAS or XLT (11 cases) and obtained from the 
archive of the Department of Pathology, Spedali Civili di Brescia. Clini-
cal and molecular data were provided for each case (Department of Pedi-
atrics, Institute of Molecular Medicine “A. Nocivelli,” University of 
Brescia, Brescia, Italy) and previously described in Wengler et al. (1995), 
Vermi et al. (1999), and Jin et al. (2004). Normal spleen from age-
matched control patients (10 cases) who underwent splenectomy for trauma 
or spherocytosis were used for comparison. Peripheral blood samples 
were collected according to the protocol for research studies on biologi-
cal material from patients with primary immunodeficiency (TIGET 02), 
including WAS, approved by the HSR Institutional Ethical Committee. 
Biological specimen from HDs (children) were collected and used upon 
informed consent for research purpose in agreement with the rules de-
fined by approved protocols TIGET PERIBLOOD. For pDC isolation, 
CD3+, CD14+, CD15+, CD19+, and CD56+ cells were depleted from 
PBMCs using magnetic beads (Miltenyi Biotec). CD3/CD14/CD15/
CD19/CD56 cells were stained with PE-conjugated anti–BDCA-2 
(Miltenyi Biotec), and BDCA-2+ cells were isolated using anti-PE mag-
netic beads (Miltenyi Biotec).
Immunohistochemistry. 4-µm formalin-fixed paraffin-embedded tissue 
sections were stained with anti-BDCA2 (mouse IgG1, clone 124B3.13, di-
lution 1:50; Dendritics), and anti-MxA (mouse IgG2a, dilution 1:500, pro-
vided by O. Haller, University of Freiburg, Freiburg, Germany). Epitope 
retrieval was obtained by microwave heating in EDTA buffer, pH 8.0, for 
3 × 5 min, at 750 W for anti-MxA and for 2 × 5 min at JET and 3 × 5 min 
at 750 W for anti-CD303. Reactivity was revealed using the EnVision anti–
mouse HRP-linked detection kit (Dako) for anti-MXA or Bond Polymer 
Refine Detection (Leica) for anti-BDCA2 followed by DAB. Distribution 
of PDC was analyzed by double immunohistochemistry using primary anti-
body to BDCA2 and CD3 (rabbit, clone SP7, dilution 1:100; Thermo Fisher 
Scientific). After completing the first immune reaction against BDCA2, the 
second immune reaction was visualized using Mach 4 MR-AP (Biocare 
Medical), followed by Ferangi Blue (Biocare Medical) as chromogen. Absolute 
PDC count was quantified automatically applying a custom-programmed 
script in Cognition Network Language based on the Definiens Cognition 
Network Technology platform (Definiens AG). In brief, digital slides of 
entire spleen sections immunostained for CD303 were obtained by Aperio 
ScanScope CS Slide Scanner (Aperio Technologies) at 40× magnification 
and analyzed using Tissue Studio 2.0 (Definiens AG). The quantitative scor-
ing algorithm for BDCA2 was customized by using commercially available 
templates. The algorithm was created to match the requirements of the 
CD303 staining parameter in human spleen and includes Manual ROI 
Selection (Draw Polygon). PDCs are expressed as number of CD303-positive 
cells/mm2 of spleen area. Spleen MxA expression was scored as percentage 
of positive cells: positivity score 1 = <25% of positive cells; score 2 = 25–50% 
of positive cells; score 3 = >50% of positive cells; score 4 = >75% of positive 
cells. As an additional strategy, we also measured total MxA signal by Tissue 
Studio 2.0 (Definiens AG) on spleen digital slides immunostained for MxA. 
The algorithm was created to match the requirements of the MxA staining 
parameter in spleen sections and includes Manual ROI Selection (Draw 
Polygon). Data are expressed as percentage of spleen area immunostained 
for MxA.
For figure panel preparation, immunostained sections were photo-
graphed using a digital camera (DP-70; Olympus) mounted on a micro-
scope (BX60; Olympus) and processed using Analysis Image Processing 
software (Olympus). Scoring of the T cell infiltration was performed on 
formalin-fixed paraffin-embedded sections of mice large bowel. 4-µm 
sections were stained with anti-CD3 (rabbit monoclonal, clone SP7, 
dilution 1:100; Thermo Fisher Scientific). Antigen retrieval was ob-
tained by microwave heating in EDTA buffer, pH 8.0, for 3 × 5 min at 
750 W, and reactivity was revealed using EnVision HRP-linked detec-
tion system (Dako) followed by diaminobenzidine (DAB). Nuclei were 
counterstained with hematoxylin. T cells were quantified on at least 
10 HPF/mouse.
Analysis of pDC frequency in human peripheral blood. Immunophe-
notyping of human pDCs was performed using the following anti–human 
antibodies: APC-conjugated anti-CD3/anti-CD14/anti-CD15/anti-CD16/
anti-CD19/anti-CD20/anti-CD56 (lineage cocktail; BD); PE-conjugated 
anti-BDCA-2 (Miltenyi Biotec); and PE-Cy7–conjugated anti-CD4 (BD; 
Presicce et al., 2008). The pDC subset was identified as lineage cocktail–
negative/BDCA-2+/CD4+ cells gated on live cells. Stained cells were ac-
quired with a FACS CANTO flow cytometer and analyzed with FCS 
Express software (version 2.3; De Novo Software). Isotype controls were 
performed with corresponding mouse Ig.
370 Role of WASp in pDCs | Prete et al.
water for 7 d and then sacrificed. BrdU incorporation in spleen, lymph 
node, and BM cells was determined using the FITC BrdU flow kit (BD). 
For cell death analysis, splenocytes stained with antibodies to CD11c, 
B220, and PDCA-1 were labeled with FITC-conjugated annexin V and 
7-amino-actinomycin D (7-AAD; BD). Dead cells were defined as 7-AAD+ 
cells and apoptotic cells as 7-AAD annexin V+.
FACS analysis. The following Abs for FACS analysis were purchased 
from BioLegend: PE-conjugated Sca-1; PE-Cy7–, FITC-, and PE-conjugated 
anti-CD11c; FITC- and PE-Cy5–conjugated anti I-Ab; PE- and PE-
Cy5–conjugated anti-CD86; PE-Cy5–conjugated anti-CD40; PE- and 
FITC-conjugated anti-B220; FITC- and APC-conjugated anti–PDCA-1; 
PE-Cy5–conjugated anti-CD19; FITC- and APC-conjugated anti-CD3; and 
PE-Cy7–conjugated anti-TNF. Anti–IFN- RMMA-1 was from PBL Bio-
medical Laboratories, Inc. FITC-conjugated anti-WASp was purchased 
from Santa Cruz Biotechnology, Inc. For analysis of number and activation 
of pDCs, total cells freshly isolated from spleen, lymph nodes, and blood 
were stained for 30 min at 4°C with antibodies to extracellular markers 
CD11c, B220, and PDCA-1 for the detection of pDC subset and with anti-
bodies to CD86, CD40, or I-Ab for the analysis of the maturation state. 
Stained cells were acquired with a FACSAria III flow cytometer and ana-
lyzed with FLOWJO software (version 4.5.4; Tree Star). Isotype controls 
were performed with corresponding rat Ig. For detection of intracellular 
IFN- in splenic pDCs, 10 µg/ml Brefeldin A (Sigma-Aldrich) was added 
during all the phases of DC enrichment procedure and staining. Cells were 
enriched from total spleen cells by depletion of B and T cells and stained for 
extracellular markers using antibodies to CD11c, B220, and PDCA-1. Cells 
were then processed with the Fix & Perm kit (BD) according to the manu-
facturer’s instructions and then stained overnight at 4°C with an anti–IFN- 
antibody. For detection of intracellular IFN- and TNF by BM-pDC, cells 
were stimulated with 20 µg/ml CpG-A for 5 h at 37°C in the presence of 
10 µg/ml Brefeldin A. Cells were processed with the Fix & Perm kit and 
then stained over night at 4°C with anti–IFN- and anti-TNF antibodies.
RNA extraction and real-time polymerase chain reaction. Total RNA 
from isolated endogenous pDCs of pooled mice (n = 4) was prepared with 
TRIzol (Invitrogen) and treated with DNase I (Fermentas) according to the 
manufacturer’s protocol. cDNA was synthesized with random hexamers and 
M-MLV reverse transcription (Invitrogen). Quantitative real-time PCR analysis 
was performed with the CFX96 Touch Real-Time PCR Detection System 
and iQ SYBR green Supermix (Bio-Rad Laboratories). -actin mRNA was 
used for normalization of Ifn4 and Il6 mRNA expression. Primer se-
quences were as follows: IFN-4 forward, 5-CCTGTGTGATGCAGG-
AACC-3, and reverse, 5-TCACCTCCCAGGCACAGA-3; IL-6 forward, 
5-GAGGATACCACTCCCAACAGA-3, and reverse, 5-AAGTGCAT-
CATCGTTGTTCAT-3; -actin forward, 5-CAGAAGGAGATTACT-
GCTCTGGCT-3 and reverse, 5-GGAGCCACCGATCCACACA-3. 
Thermal cycle conditions were the following: 95°C for 3 min, 43 cycles of 
95°C for 10 s, and 60°C for 30 s. Each sample was analyzed in duplicates, and 
the relative expression of target genes were defined by calculating the  cycle 
threshold, with respect to the housekeeping gene.
Silencing of WASp. ONE-TARGET plus siRNA targeting WASp and 
ONE-TARGETING plus nontargeting siRNA (Thermo Fisher Scientific; 
Dharmacon RNAi Technology) and used as specific WASp siRNA and as 
control siRNA, respectively. 8 × 106 BM-pDCs or -cDCs were transfected 
with 10 µM siRNA using the Nucleofector (Amaxa) according to the man-
ufacturer’s instructions. Cells were collected 48 h after transfection. To assess 
depletion of WASp, 3 × 105 cells were lysed and analyzed by SDS page using 
anti-WASp antibody (Santa Cruz Biotechnology, Inc.). Protein reduction 
was assessed by ImageJ (National Institutes of Health).
Cytochalasin-d and latrunculin-A treatment. BM-pDCs and -cDCs 
were plated in 96-well culture plates in complete medium including 1 µg/ml 
cytochalasin d (Sigma-Aldrich) or 0.1 µM latrunculin-A (AdipoGen) for 
IFN- induction. 5 × 105 PBMCs were stimulated using 5 µM CpG ODN 
2216 (Enzo Life Sciences) in 96-well plates at a final volume of 200 µl/well. 
Afterward, 24 supernatants were collected and stored at 80°C. For IFN- 
induction in pDCs by serum, 2 × 105 BDCA-2+ cells were incubated with 
50% serum at a final volume of 200 µl/well. Afterward, 24 supernatants were 
collected and stored at 80°C. The amount of IFN- was measured in the 
supernatant by ELISA (Verikine Human IFN Alpha Serum Sample ELISA 
kit; PBL InterferonSource).
Analysis of gene expression profile in PBMCs. mRNA was extracted from 
PBMCs of WAS patients and HDs using RNeasy Mini kit (QIAGEN). Ret-
rotranscription was performed using the RT2 First Strand kit (SABiosciences). 
Real-time PCR on cDNA samples was performed according to the protocol 
provided with the kit (Human IFN-, - Response PCR Array; SABiosciences) 
on a ViiA 7 Real-Time PCR System (Life Technologies). Ct values were calcu-
lated for each target gene by normalizing the Ct value of the target gene to the 
Ct value of the housekeeping gene. Ct values were calculated for each target 
gene by normalizing the WAS patient Ct value to the mean Ct value of the 
same gene expressed by healthy controls. Fold increase values were calculated for 
each target gene using the following formula: 2(Ct).
Mice. WASp/ (WKO) mice on a C57BL/6 (CD45.2) genetic back-
ground were a gift from S. Snapper (Massachusetts General Hospital, 
Boston, MA). Mice were bred and maintained in sterile isolators. In vivo 
experiments were performed using WASP/ homozygous female or 
WASp male as WKO and WT littermate as control. Mice lacking the 
-chain of the IFN-/ receptor on a B6 background were provided by U. 
Kalinke and bred with the WASp/ mice to generate IFNAR//WASp/ 
double KO (DKO) mice. Animal care and treatment were conducted in 
conformity with institutional guidelines in compliance with national and in-
ternational laws and policies (European Economic Community Council Di-
rective 86/609; OJL 358; December 12, 1987). Protocols were approved by 
the Italian Ministry of Health.
Cells. BM-derived pDCs and cDCs were differentiated in vitro from the 
BM of WT or WASp KO mice using FLT-3 ligand. DCs were used for ex-
periments between days 6 and 8. BM-pDC and BM-cDC were obtained by 
positive and negative selection, respectively, using B220+ microbeads (Miltenyi 
Biotec). For isolation of pDCs from organs, cell suspension were obtained by 
digestion with 1.6 mg/ml collagenase d (Roche) and 0.1 mg/ml DNase I 
(Roche) for 30 min at 37°C. Splenic pDCs were enriched from total spleen 
cells using the Plasmacytoid Dendritic Cell Isolation kit II, mouse (Miltenyi 
Biotec). In some experiments, CD11c+/PDCA-1+/B220+ cells were isolated 
from B and T cell–depleted spleen cells or total lymph node cell suspensions 
using a FACSAria III cell sorter (BD). Purity was higher that 95%.
TLR agonists. The CpG-A (1585) and CpG-B (1826) oligonucleotides 
and R837 were from InvivoGen. The Cy5-labeled CpG-A was obtained 
from Sigma-Aldrich. FITC-CpG-A was from InvivoGen. The lipopolysac-
charide (Escherichia coli O55:B5) was from Enzo Life Sciences.
In vivo treatment. Mice were injected in the tail vein with CpG-A com-
plexed with the cationic lipid 1,2-dioleoyloxy-3-trimethylammonium-propane 
(DOTAP). For preparation of CpG-A/DOTAP mixture, 10 µg CpG-A re-
solved in 50 µl PBS was incubated with 30 µl (30 µg) DOTAP Liposomal 
Transfection Reagent (Roche) in a polystyrene tube containing 70 µl PBS for 15 
min at room temperature. 150 µl of the CpG-A/DOTAP mixture was then in-
jected. Sera were collected 2, 6, 10, and 24 h after the CpG-A/DOTAP injec-
tion and analyzed for the content of IFN-, IL-6, and IL-12p40. For the 
detection of intracellular IFN-, spleens are collected 45 min, 2 h, and 30 min 
or 6 h after the injection. Cytokine ELISA kits were purchased from PBL Bio-
medical Laboratories (IFN-) and Thermo Fisher Scientific (IL-12p40 and IL-6).
BrdU incorporation. For continuous in vivo BrdU labeling, mice were 
fed 1 mg/ml BrdU (Sigma-Aldrich) in 10% sucrose-supplemented drinking 
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Immunoprecipitation of WASp. 8 × 106 WT BM-DCs were resuspended 
in complete IMDM supplemented with Flt3 ligand and incubated with CpG-A 
at 20 µg/ml for 3, 7, or 10 min at 37°C. Cells were washed and lysed with 
NP-40 plus phosphatase inhibitors. Total lysates were subjected to overnight 
incubation at 4°C with protein A–Sepharose beads (GE Healthcare) previously 
treated for 2 h with 2 µg of polyclonal anti-WASp (H-250; Santa Cruz Bio-
technology, Inc.). Bead–antibody–protein complexes were washed four times 
with lysis buffer and eluted with SDS-PAGE sample buffer. Immunoprecipi-
tated proteins were separated by SDS-PAGE using 7.5% polyacrylamide gel. 
Anti-phosphotyrosine and anti-WASp immunoblotting was performed using 
an anti–P-tyrosine (P-Tyr-100; Cell Signaling) and an anti-WASp monoclo-
nal antibody (B-9; Santa Cruz Biotechnology, Inc.), respectively.
Immunofluorescence analysis. For the analysis of intracellular trafficking 
of CpG-A, splenic pDCs were isolated form the spleen of young animals 
(3 wk). Cells were pulsed with 10–20 µg/ml FITC-labeled CpG-A for 
30 min to 2 h as indicated in the text. In experiments with drug inhibitors, 
cells were incubated with cytochalasin-d for 30 min before incubation with 
CpG-A. For siRNA experiment control and WASp-specific siRNA, treated 
BM-pDCs or WT BM-pDCs were incubated with 3 µM CpG-cy5 (Sigma-
Aldrich). For IRF-7, nuclear translocation cells were incubated with unla-
beled CpG-A for 2 h. Fixed cells were labeled with goat anti–EEA-1 (Santa 
Cruz Biotechnology, Inc), LAMP-1 (553792; BD; directly coupled to Alexa 
Fluor 555 to avoid cross reactivity with antibodies used for isolation), or anti 
IRF-7 (Invitrogen). Confocal images were acquired in a reverse microscope 
(LSM 510 META Axiovert 200M; Carl Zeiss) with a 63× objective. EE 
volumes and CpG-A volumes were quantified on projections of 0.2 z 
slices using Volocity software (Perkin Elmer, Inc). Colocalization between 
CpG-A and endosomes markers was measured manually on 3D recon-
structed images, using Volocity software. To quantify nuclear translocation 
of IRF-7, we manually depicted two regions, one including the nucleus 
(based on DAPI signal) and the second covering the cytosol. The ratio be-
tween the intensities in the two regions was calculated and expressed as index 
of nuclear translocation.
Statistical analysis. Results were analyzed with Prism 5.0 (GraphPad Soft-
ware). The tests used for statistical analysis are mentioned in the figure leg-
ends. A p-value <0.05 was taken as statistically significant. All graphs, unless 
otherwise specified, show mean ± SEM.
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